Monitor the Special Committee’s recommendation regarding the proposed related-party intellectual property acquisition, as this will serve as a key test of the effectiveness of the Company’s newly established independent board oversight process.
POLOMAR HEALTH SVCS INC
Company and security reference data from OTC Markets Group.
Alerted 8k 7/302026 Price 0.15 8/4/26
DD entries are user-generated due diligence, not investment advice. Moderated. Filings link to sec.gov.
No level shown - warrant disclosures, preferred stock disclosures and convertible note disclosures could not be read reliably from this filing. The extracted facts are below.
From 10-Q filed Jun 1, 2026View filing
Level = disclosed potential new shares (warrants + preferred conversion shares + shares issuable from convertible notes, where the filing states them) divided by shares outstanding:
under 10% = Low · 10-50% = Moderate · 50-200% = Elevated · over 200% = Substantial
Only figures stated explicitly in the filing are used - nothing is estimated. A level is shown only when the share count was read with high confidence AND each of convertibles, warrants, and preferred stock was either clearly disclosed or affirmatively stated as none by the filing. If any of the three could not be read reliably, no level is shown at all - partial data never produces a label. Authorized headroom is shown as a separate fact and is not part of the level. Convertible note principal (dollars) is never converted into shares.
Figures are AI-extracted from the company's own SEC filings and may contain errors - always verify against the linked filing. This is not investment advice.